STAGE IIIB BLADDER CANCER AJCC V8
Clinical trials for STAGE IIIB BLADDER CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IIIB BLADDER CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IIIB BLADDER CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New triple therapy aims to tame immunotherapy side effects in advanced cancers
Disease control OngoingThis study tests whether adding tocilizumab to two standard immunotherapy drugs (ipilimumab and nivolumab) can reduce severe side effects while still fighting cancer. About 35 adults with advanced melanoma, non-small cell lung cancer, or bladder cancer will receive the combinatio…
Matched conditions: STAGE IIIB BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 14:22 UTC
-
Can a gene test tell who will benefit from immunotherapy?
Knowledge-focused OngoingThis study looks at whether certain genetic changes in tumors can help predict how well the immunotherapy drug nivolumab works for people with advanced bladder cancer that has spread. Researchers are focusing on two genes, ARID1A and KDM6A, and a protein called CXCL13. The goal i…
Matched conditions: STAGE IIIB BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated May 11, 2026 20:48 UTC